HealthcareMental HealthHow Telehealth Changed Addiction-treatment Intake

By Ann Mendenhall, PA

A patient once told me she had sat in a parking lot outside a treatment center three separate times before driving home without going in. The fourth time, she did not have to get out of the car at all. She did her first screening from her phone, in the same parking lot, and by the end of that call we had a plan. That shift, from a door she could not make herself open to a video window she could close at any moment, is the part of addiction treatment that virtual care has reordered most quietly and most completely.

Intake used to be the chokepoint. Before a person could start medication for opioid use disorder, federal rules required an in-person visit with a clinician first. The pandemic-era prescribing flexibilities changed that, letting clinicians remotely evaluate and start patients on buprenorphine without an in-person exam and expanding payment for telehealth across the board. The National Institute on Drug Abuse documented what happened next: in a Medicaid analysis across Kentucky and Ohio, people who started buprenorphine through telehealth were more likely to stay in care for a continuous 90 days. In Kentucky the figure was 48 percent for the telehealth group versus 44 percent for in-person starts, and in Ohio it was 32 percent versus 28 percent. Telehealth initiation was also not linked to any increased likelihood of nonfatal overdose, which matters, because the first question every cautious clinician asks about remote intake is whether speed comes at the cost of safety.

Why the first contact is where the gains are

The scale of the problem sits in front of every intake decision. SAMHSA reported from its 2024 national survey that 80 percent of people who needed treatment for a substance use disorder did not get it. A gap that wide comes less from a shortage of beds or clinical skill than from a simpler failure: a large share of people never make the first contact at all. NIDA also notes that more than 46 million people in the United States had at least one substance use disorder in 2021, and that stigma makes individuals with these disorders less likely to seek treatment in the first place.

Virtual screening attacks that first-contact failure directly. The person does not have to plan a day off, arrange a ride, sit in a waiting room where someone might recognize them, or rehearse what they will say to a receptionist. They can answer a structured set of questions from a closed bedroom door. In my own intake calls, people disclose use patterns earlier and more honestly over video than they historically did across a desk, partly because the home setting lowers the temperature of the conversation. The shame barrier does not vanish. It moves. A patient who would have ghosted an in-person assessment will often stay on a call that started as “just information.”

What virtual intake actually compresses

The practical wins are about timing. A traditional intake might run a week or more from first phone call to scheduled assessment to admission decision. Remote screening collapses that into a single sitting. We can run an initial clinical interview, gauge withdrawal risk, verify benefits, and route the person to the right level of care in one conversation rather than across three appointments that each create a fresh chance to drop out. Same-day or next-day starts become realistic, and in addiction medicine the interval between “I am ready” and “I have started” is the most dangerous gap there is. Every day of delay is a day the window can close.

Faster scheduling also lets a clinician match the patient to setting more accurately on the first pass. Someone describing daily heavy alcohol use and morning shakes is not a candidate for a purely remote pathway, and the screening is precisely where that gets caught. A provider such as pvrecovery.com in Santa Rosa, California, runs the full continuum, from medically supervised detox and residential care through intensive outpatient, medication-assisted treatment, and sober living, which is what makes a virtual first step coherent. The screen is only worth speeding up if there is somewhere to route every kind of answer it produces.

The limits worth stating plainly

Telehealth reshaped the front door. It did not replace the building. Some assessments still require hands and eyes in a room. You cannot fully gauge a patient at real risk of severe alcohol or benzodiazepine withdrawal over video, where seizures and delirium are genuine medical emergencies, and you cannot conduct medically supervised detox through a screen. Vital signs, a physical exam, observed dosing, and a bed for the night are in-person functions, and pretending otherwise puts people in danger.

The access gains are also uneven. The same NIDA analysis found that some groups, including non-Hispanic Black individuals, men, and people with a prior opioid overdose, were both less likely to receive treatment via telehealth and less likely to stay in care through 90 days. A delivery method that widens access on average can still leave specific populations further behind, and the people most likely to lack a private device or stable connection are often the ones a remote front door was supposed to reach.

The honest framing is narrow and worth holding onto. Virtual screening and intake is a remarkably effective on-ramp. It finds people earlier, it lowers the cost of asking for help, and it shortens the dangerous wait between decision and treatment. What happens after the on-ramp, especially detox and the stabilization of high-acuity patients, still belongs in a clinic with staff who can put a hand on someone’s shoulder. The programs getting the most out of telehealth are the ones that treat it as the entrance and keep the clinical capacity behind it fully staffed. The screen gets people in the door. The door still has to lead somewhere real.